Founder profile
Darius Walker, Ph.D.
✓ PUBLICPublic-safe venture information · deeper artifacts remain private
UNCLAIMED VENTUREHome ↗A biotechnology company developing small-molecule therapies that target multiple immune pathways in autoimmune disease.
This venture has not been claimed, so no Proof Score has been calculated for it. f3 scores from verified evidence — never from an estimate.
If this is yours, claim it →◇ f3 publishes no Proof Score for an unclaimed venture. A score is calculated from verified evidence only after the founder claims this profile.
“Vimelea Therapeutics is developing a novel platform of small molecules for inflammatory disease, with cutaneous lupus erythematosus as a public lead focus.”
The scientific premise targets multiple immune pathways while pursuing compounds designed to act in unbalanced immune tissue.
Only public, non-financial facts are shown in this preliminary cohort view.
Darius Walker, Ph.D.
✓ PUBLICOfficial public destination
✓ LIVEAutoimmune therapeutics
✓ PUBLICLIFT · TiE Atlanta
✓ ACKNOWLEDGEDEvidence profile in progress
✓ UNSCORED
Founder title pending · Vimelea Therapeutics
Profile update pending: founder title.
These are independent industry baselines—not company performance, valuation, or a private forecast.
A CDC-registry meta-analysis estimate for people meeting systemic-lupus classification criteria.
Source: CDC Lupus Registries meta-analysis · NIH/PubMed Central ↗The prevalence range reported across population-based cutaneous-lupus studies.
Source: Cutaneous lupus review · NIH/PubMed Central ↗vimelea-thera.com
Public media can be added later.
No public deck is linked yet.
Program references are acknowledged here; the full ecosystem experience is not yet available.
Cohort program · experience coming later
Founder network · experience coming later
Artifacts, exact pillar values, and private venture data are intentionally excluded from this public cohort view.